SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

2/14/22 2:34:33 PM ET

Medical/Dental Instruments

Health Care

Get the next $ATRC alert in real time by email

SC 13G/A 1 atrc13gadec21.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) AtriCure, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 04963C209 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 482,663 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,945,751 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,945,751 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 4.2% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: AtriCure, Inc. Item 1(b) Address of Issuer's Principal Executive Offices: 7555 INNOVATION WAY, MASON, OHIO 45040 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 04963C209 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 14, 2022 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2021

Get the next $ATRC alert in real time by email

Recent Analyst Ratings for

$ATRC

Date	Price Target	Rating	Analyst
2/11/2026	$36.00	Overweight → Neutral	Analyst
12/17/2024	$40.00	Overweight	Analyst
4/23/2024	$32.00	Perform → Outperform	Oppenheimer
10/23/2023	$60.00	Mkt Outperform	JMP Securities
9/29/2023	$56.00	Buy	UBS
2/16/2022	$120.00 → $88.00	Buy	Canaccord Genuity
2/16/2022	$92.00 → $79.00	Buy	Needham
11/4/2021	$90.00 → $92.00	Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

2/14/22 2:34:33 PM ET

$ATRC

Medical/Dental Instruments

Health Care

Get the next $ATRC alert in real time by email

Recent Analyst Ratings for

$ATRC

Date	Price Target	Rating	Analyst
2/11/2026	$36.00	Overweight → Neutral	Analyst
12/17/2024	$40.00	Overweight	Analyst
4/23/2024	$32.00	Perform → Outperform	Oppenheimer
10/23/2023	$60.00	Mkt Outperform	JMP Securities
9/29/2023	$56.00	Buy	UBS
2/16/2022	$120.00 → $88.00	Buy	Canaccord Genuity
2/16/2022	$92.00 → $79.00	Buy	Needham
11/4/2021	$90.00 → $92.00	Buy	Needham

More analyst ratings

SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ATRC

SEC Form SC 13G/A filed by AtriCure Inc. (Amendment)

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ATRC

$ATRC
Press Releases

AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results

AI Diagnostics: The End of the High-Cost Imaging Era

AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026

$ATRC
SEC Filings

AtriCure Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition

SEC Form 144 filed by AtriCure Inc.

SEC Form 144 filed by AtriCure Inc.

$ATRC
Insider Trading

Chief Operating Officer Seith Douglas J was granted 257 shares, increasing direct ownership by 0.14% to 184,370 units (SEC Form 4)

President, CEO, & Director Carrel Michael H gifted 4,000 shares, decreasing direct ownership by 0.58% to 687,377 units (SEC Form 4)

Director Wehrwein Sven exercised 10,000 shares at a strike of $19.95 and sold $376,578 worth of shares (10,000 units at $37.66) (SEC Form 4)

$ATRC
Analyst Ratings

AtriCure downgraded by Analyst with a new price target

Analyst resumed coverage on AtriCure with a new price target

AtriCure upgraded by Oppenheimer with a new price target

$ATRC
Insider Purchases

Privitera Salvatore bought $111,250 worth of shares (5,000 units at $22.25), increasing direct ownership by 5% to 103,290 units (SEC Form 4)

$ATRC
Leadership Updates

AtriCure Appoints Shlomi Nachman to the Board of Directors

AtriCure Announces the Appointment of Deborah Yount as Chief Human Resources Officer

$ATRC
Large Ownership Changes

SEC Form SC 13G filed by AtriCure Inc.